What is Augmentation? How to diagnose? What to do?
|
|
- Katherine Williams
- 6 years ago
- Views:
Transcription
1 What is Augmentation? How to diagnose? What to do? Diego Garcia-Borreguero Madrid, SPAIN
2 Dopaminergics do work: The case of L-dopa ns ns p-values PLM/h Placebo L-Dopa 20 0 Benes et al, Sleep hours
3 But do dopaminergics work over the long-term? Pat 1 Pat 2 Pat BL W2 W4 W6 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52
4 Augmentation Augmentation reflects an overall increase in symptom severity as a result of longterm dopaminergic treatment Augmentation does not have distinctive features to RLS itself, but rather represents a worsening of the same symptoms that are being treated This worsening is usually slow and goes beyond baseline severity
5 (Allen et al., 1996) Augmentation First feature: rebound Earlier onset of symptoms (main, cardinal feature) hrs augmentation
6 (Allen et al., 1996) Augmentation Shorter latency to symptoms at rest Overall increase in symptom severity Longer latency until onset of therapeutic effects Expansion to arms, trunk, abdomen
7 Dopaminergic Augmentation: Frequency in clinical practice No minor problem Cumulative frequency Def. AUG 20% The risk to AUG increases during the first 8 years Partial AUG 56% No AUG 24% (Allen, Sleep Med 2011)
8 Augmentation Potential predictors: Dopaminergic treatment Short-acting drugs Dose Duration of treatment Lower ferritin at baseline Previous episodes of augmentation Previous loss of efficacy
9 Augmentation increases at higher doses n (of 49) 100 mg 0% 200 mg 14, 3% 300 mg 50% 400 mg 28,6% 500 mg 7,1% Aver. dose: 329, mg AU G mg
10 Rate of Augmentation increases over time Placebo Ropinirole Garcia-Borreguero et al., Mov Disord. 2012;27(2):277-83
11 Augmentation during treatment with Pramipexole vs Pregabalin 10 Rate of augmentation (%) % p = % p = % 0 PGB PPX 0.25 PPX 0.5 Augmentation at 40 weeks Allen et al: N Engl J Med. 2014;370(7):621-31
12 Augmentation vs. disease progression Augmentation occurs within weeks/months Disease progression occurs slowly over time (years?) Improvement of symptoms following dose reduction/ discontinuation of treatment becomes a key distinctive feature.
13 Differences between tolerance and augmentation Greater severity than at baseline Onset of symptoms earlier in the day Shorter latency to sx at rest Spread of sx to arms Augmentation Yes Yes Yes Yes Tolerance No No No No
14 Dose and augmentation/ tolerance Higher doses of dopaminergic treatment result in a higher incidence of augmentation Lower doses of dopaminergic treatment result in a higher incidence of tolerance
15 AUGMENTATION Severity Untreated Treated MPI criteria Tolerance clinically significant Sx Time
16 Early signals of Augmentation Break-through crises/ daytime symptoms Increase in symptom frequency or symptom intensity Overall decrease in therapeutic efficacy/ tolerance Shorter duration of treatment effect. Symptoms in previously unafected body parts Worsening of sleep efficacy or sleep quality Increased PLMs during sleep or wakefulness Patient requires additional medication
17 What causes augmentation? Pharmacokinetic hypothesis Based on diffence in prevalences during treatments with DA agonists (low prev.) and L- DOPA (high prevalence) Caused by repeated (= pulsatile ) administration? Downregulation of DA receptors during long-term L-DOPA treatment Related to pulsatile administration of L-DOPA? Related to dose, duration of treatment?
18 Diagnosis of Augmentation Relies on clinical judgement (MPI criteria) Structured Interview for the Diagnosis of Augmentation (based on Max-Planck criteria) Clinical trials: Expert Pannel on Augmentation Potential alternatives: Actigraphy Multiple Suggested Immobilization test BUT: None of these has been used yet in clinical studies. Evaluation of Severity: Augmentation Severity Rating Scale: ASRS
19 Prevention of augmentation 1. Keep ferritin levels within the normal range 2. Avoid SSRIs, antihistamines 3. Use long-acting dopamine agonists 4. Keep the dose low, try to stay well below the upper limit of the recommended dose range. 5. If some, but insufficient efficacy, consider combination treatment with a non-dopaminergic agent (i.e. alpha2-delta ligand)
20 Proposed Management of Augmentation First, determine ferritin levels and evaluate potential yatrogenic factors (SSRI, DA antagonists!) Mild cases: Anticipate the time of administration of DA drugs. Severe cases: Option A: Progressive withdrawal of dopaminergic drug. Combination therapy with alpha-2 delta ligands /opiates Option B: Complete interruption of DA drugs. Administration of alpha-2 delta ligands /opiates Continue options A or B for 3-6 months. Then reinitiate treatment with a different dopaminergic agent. If augmentation reappears, continue monotherapy with opiates/alpha-2 delta ligands either as monotherapy or in combination with low doses of dopaminergic drugs.
Christopher J. Earley, MB, BCh, PhD Professor Department of Neurology Johns Hopkins School of Medicine
Christopher J. Earley, MB, BCh, PhD Professor Department of Neurology Johns Hopkins School of Medicine 1. Medication working well but do you still need it? 2. Medication working well but do you really
More informationBasics of Restless Legs Syndrome (Willis-Ekbom Disease)
Basics of Restless Legs Syndrome (Willis-Ekbom Disease) Michael H. Silber, M.B.Ch.B. Professor of Neurology Mayo Clinic College of Medicine Objectives Understand how RLS is diagnosed Understand what we
More informationAUGMENTATION SUFFERING AND WHAT CAN BE DONE ABOUT IT. John W. Winkelman MD PhD Massachusetts General Hospital Harvard Medical School Boston, MA
AUGMENTATION SUFFERING AND WHAT CAN BE DONE ABOUT IT John W. Winkelman MD PhD Massachusetts General Hospital Harvard Medical School Boston, MA Disclosure Information Type of Affiliation Commercial Entity
More informationThe Prevention & Treatment of Augmentation
The Prevention & Treatment of Augmentation MARK J BUCHFUHRER, MD S T A N F O R D U N I VERSITY S L E E P M E D I C IN E C E N T ER, R E D W O O D C I T Y, C A P R I VATE P R ACTICE, D O W N E Y, C A 2017
More informationNew data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome
New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome Latest safety and efficacy results for rotigotine in the treatment of moderate to
More informationThe Management of Restless Legs Syndrome in Adults in Primary Care Version 1.1 February 2019
The Management of Restless Legs Syndrome in Adults in Primary Care Version 1.1 February 2019 VERSION CONTROL Version Number Date Amendments made 1.0 December 2015 1.1 February 2019 Version 1. Approved
More informationParkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute
Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute Parkinson s Disease 2 nd most common neurodegenerative disorder Peak age at onset is 60 years
More informationCase 1. A. Insomnia B. Restless leg syndrome C. Peripheral neuropathy D. Osteoarthritis of the hip. Disclosures. Diagnosis for trouble falling asleep
Disclosures I have no disclosures Case 1 Liza Ashbrook, MD Assistant Clinical Professor UCSF Department of Neurology History of Present Illness Diagnosis for trouble falling asleep 70-year-man with obstructive
More informationContinuous dopaminergic stimulation
Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa
More informationORIGINAL COMMUNICATION. J Neurol (2010) 257: DOI /s
J Neurol (2010) 257:230 237 DOI 10.1007/s00415-009-5299-8 ORIGINAL COMMUNICATION Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a
More informationLong-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation
CNS Drugs (2015) 29:351 357 DOI 10.1007/s40263-015-0250-2 CURRENT OPINION Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation
More informationRestless Legs Syndrome. Brian Koo, M.D. University Hospitals
Restless Legs Syndrome Brian Koo, M.D. University Hospitals Outline of Talk Diagnosis/classification Symptomatology Evaluation PLMS Epidemiology Prevalence Risk factor Effect of Quality of Life Pathophysiology
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationComparison of Pregabalin with Pramipexole for Restless Legs Syndrome
original article Comparison of with Pramipexole for Restless Legs Syndrome Richard P. Allen, Ph.D., Crystal Chen, M.D., Diego Garcia-Borreguero, M.D., Ph.D., Olli Polo, M.D., Sarah DuBrava, M.S., Jeffrey
More informationDiego Garcia-Borreguero a *, Michael H. Silber b,, John W. Winkelman c,d, Birgit Högl
Guidelines for the first-line treatment of RLS/WED, prevention and treatment of dopaminergic augmentation A combined task force of the IRLSSG, EURLSSG, and the RLS-Foundation Diego Garcia-Borreguero a
More informationTitle: Guidelines for the first-line treatment of restless legs syndrome/willisekbom disease, prevention and treatment of dopaminergic augmentation
Accepted Manuscript Title: Guidelines for the first-line treatment of restless legs syndrome/willisekbom disease, prevention and treatment of dopaminergic augmentation Author: Diego Garcia-Borreguero,
More informationCan valium help restless leg syndrome
Can valium help restless leg syndrome The Borg System is 100 % Can valium help restless leg syndrome Mar 1, 2012. Fortunately, certain lifestyle strategies can help you manage milder forms of RLS, and
More informationData presented at major international congress
Neupro (rotigotine transdermal system) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Legs Syndrome Data presented at major international congress
More informationRESTLESS LEGS SYNDROME IN CHILDREN AND ADOLESCENTS
RESTLESS LEGS SYNDROME IN CHILDREN AND ADOLESCENTS Tracy Carbone, MD Medical Director of Sleep Medicine Lee Health Golisano Children s Hospital of Southwest Florida Fort Myers, FL OVERVIEW Although the
More informationSchlafstörungen aus Neurologischer Sicht
Schlafstörungen aus Neurologischer Sicht Birgit Högl Department of Neurology Innsbruck Medical University, Austria birgit.ho@i-med.ac.at Restless Legs Syndrome / Willis-Ekbom Disease www.willis-ekbom.com
More informationTreatment of sleep disorders in
Treatment of sleep disorders in Parkinson s s disease (PD) K. Ray Chaudhuri London, UK GPSRC CNS 176 0709 RTG 1 Managing insomnia in PD Onset/initiation Adjustment of anti-pd treatment Sleep hygiene Hypnotics
More informationMISCELLANEOUS AGENTS - ALPHA-AGONISTS
Documentation A. FDA Approved Indications ADHD (Clonidine, Guanfacine) Documentation B. Non-FDA approved, commonly used psychiatric indications 1. Alcohol and opiate dependence 2. Opioid withdrawal 3.
More informationWeaning off requip. Cari untuk: Cari Cari
Cari untuk: Cari Cari Weaning off requip Weaning Off Mirapex. Readers have updated us on their weaning efforts. Mirapex has. I do not want to replace this med with Requip,. The pramipexole is the same
More informationTREATMENT OF RLS AND PLMS DISORDER IN ADULTS: PRACTICE PARAMETERS
TREATMENT OF RLS AND PLMS DISORDER IN ADULTS: PRACTICE PARAMETERS http://dx.doi.org/10.5665/sleep.1988 The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults An Update for
More informationNew concepts in the management of restless legs syndrome
New concepts in the management of restless legs syndrome Diego Garcia-Borreguero, Irene Cano-Pumarega Sleep Research Institute, Madrid 28036, Spain Correspondence to: D Garcia- Borreguero dgb@iis.es Cite
More informationRESTLESS LEGS SYNDROME AMONG THE ELDERLY
REVIEW ARTICLE RESTLESS LEGS SYNDROME AMONG THE ELDERLY Pei-Hao Chen 1,2, Shih-Jung Cheng 1,2 * 1 Department of Neurology, Mackay Memorial Hospital, and 2 Mackay Medicine, Nursing and Management College,
More informationRestless Legs Syndrome: What is Ferritin & Why Do We Want To Be Iron Man or Iron Woman
Restless Legs Syndrome: What is Ferritin & Why Do We Want To Be Iron Man or Iron Woman Focus Fall 2017 Conference Poughkeepsie, NY Dr. Steven A Thau MD Director, Pulmonary and Sleep Medicine Phelps Memorial
More informationPatients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment
For the attention of accredited medical writers only Patients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment Data presented at the 7
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationDrugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD
Drugs, Sleep & Wakefulness Brian Koo Reena Mehra MD MS Kingman Strohl MD Things To Keep In Mind Many drugs effect sleep either causing insomnia or sedation Disruption of sleep and wakefulness may not be
More informationOverview. Sleep Related Movement Disorders - Restless Leg Syndrome - Periodic Limb movements in Sleep
The Structure of Sleep The Parasomnias - in REM - in Non-REM - Narcolepsy Overview Sleep Related Movement Disorders - Restless Leg Syndrome - Periodic Limb movements in Sleep Circadian Rhythm disorders
More informationDr Alex Bartle. Medical Director Sleep Well Clinic Christchurch
Dr Alex Bartle Medical Director Sleep Well Clinic Christchurch 8:30-9:25 WS #191: Sleep Disorders in The Elderly 9:35-10:30 WS #203: Sleep Disorders in The Elderly (Repeated) REM - Rapid Eye Movement
More informationDisclosures. Speaker: Teva, UCB, Purdue Advisory Board: Welltrinsic Sleep Network Consultant: Vapotherm, Inc. National Interpretor: Novasom
So PAP Doesn t Work Rochelle Goldberg, MD, FAASM, FCCP Diplomat, American Board of Sleep Medicine Director Sleep Medicine Services Main Line Health Systems Lankenau Medical Center and Paoli Hospital Disclosures
More informationPregabalin for restless legs syndrome: A meta-analysis
Neurology Asia 2018; 23(1) : 27 33 Pregabalin for restless legs syndrome: A meta-analysis 1 Rosemarylin L Or MD FPNA, 2 Aaron Mark Hernandez MD FPCP, 1 Anthony Piano MD FPNA 1 Department of Neurology,
More informationOBJECTIVES. The psychiatric, medical, and neurologic causes of sleep problems. Office-based and objective methods of evaluating sleep
SLEEP ISSUES 1 OBJECTIVES 2 Know and understand: Age-related changes in sleep The psychiatric, medical, and neurologic causes of sleep problems Office-based and objective methods of evaluating sleep Appropriate
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST
ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST Investor Webcast July 2016 Copyright The following information contains certain forward-looking statements, relating to the company s business, which can
More informationDepression and RLS. John W. Winkelman MD, PhD Departments of Psychiatry and Neurology Massachusetts General Hospital
Depression and RLS John W. Winkelman MD, PhD Departments of Psychiatry and Neurology Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School A 42 year old man has a three
More informationRestless Legs Syndrome
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Restless Legs Syndrome Diagnosis With the emergence
More informationSedative-Hypnotics. Sedative Agents (General Considerations)
Sedative Agents (General Considerations) No best sedative agent Any agent given in sufficient dosage can produce any level of sedation Intravenous dosing is more predictable then intramuscular or oral
More informationINSOMNIA IN GERIATRICS. Presented By: Sara Kamalfar MD, Geriatrics Medicine Fellow
INSOMNIA IN GERIATRICS Presented By: Sara Kamalfar MD, Geriatrics Medicine Fellow Insomnia Insomnia is the inability to fall asleep, the inability to stay asleep, or waking up earlier than desired. To
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationR E S T L E S S L E G S S Y N D R O M E. Causes, diagnosis and treatment. For the patient living with restless legs syndrome (RLS)
R E S T L E S S L E G S S Y N D R O M E Causes, diagnosis and treatment For the patient living with restless legs syndrome (RLS) www.rls.org RESTLESS LEGS SYNDROME Restless legs syndrome (RLS), also called
More informationWhere do you get most of your information about medications?
DRUG ACTION AND RLS Jacquelyn Bainbridge, Pharm.D., FCCP Professor Pei Shieen Wong, Pharm.D., BCPS University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences,
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationRestless Leg Syndrome The Role of SIBO and Inflammation
Lincoln College of Postprofessional, Graduate and Continuing Education Restless Leg Syndrome The Role of SIBO and Inflammation Instructor: Leonard Weinstock, MD, FACG Faculty and Instructors representing
More informationRopinirole and pramipexole: first dopamine agonists for RLS
Ropinirole and pramipexole: first dopamine agonists for RLS Ropinirole (Adartrel) and pramipexole (Mirapexin) are two dopamine agonists recently licensed for the treatment of moderate to severe idiopathic
More informationNeupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease
For the attention of accredited medical writers only Neupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease Detailed
More informationUPDATE: DIAGNOSIS & MANAGEMENT OF RLS
UPDATE: DIAGNOSIS & MANAGEMENT OF RLS Beenish K. Khwaja, D.O. Legacy Medical Group--Neurology & Sleep Medicine Director, Legacy Mt. Hood Sleep Center Outline Definition & Diagnostic Criteria Epidemiology
More informationA Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
REVIEW ARTICLE Drug Saf 2011; 34 (9): 709-731 0114-5916/11/0009-0709/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationIndex. sleep.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Actigraphy, 475, 485, 496 Adolescents, sleep disorders in, 576 578 Adults, sleep disorders in, 578 580 Advanced sleep phase disorder, 482 Age,
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationINSOMNIA IN THE GERIATRIC POPULATION. Shannon Bush, MS4
INSOMNIA IN THE GERIATRIC POPULATION Shannon Bush, MS4 CHANGES IN SLEEP ARCHITECTURE 2 Reduction in slow wave sleep (stage 3 and 4) Increase in lighter stages of sleep (stage 1 and 2) Decrease in REM sleep
More informationOverview of Sleep Medicine
Overview of Sleep Medicine Rodney Smith. New York Times 11-18-2007 James E. Mojica, MD, FAASM Pulmonary, Sleep, Critical Care Massachusetts General Hospital Sleep Reversible state Perceptual disengagement
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationDiabetic Painful Neuropathy and Restless Legs Syndrome in Diabetes
Diabetes Ther (2018) 9:441 447 https://doi.org/10.1007/s13300-018-0376-6 EDITORIAL Diabetic Painful Neuropathy and Restless Legs Syndrome in Diabetes Sanjay Kalra. Anu Gupta Received: January 22, 2018
More informationMedications to Expedite Rehabilitation of the Traumatic Brain Injury Patient
Medications to Expedite Rehabilitation of the Traumatic Brain Injury Patient Austin Trauma & Critical Care Conference May 31, 2018 Kristin Wong, MD, FAAPMR Assistant Professor, Physical Medicine & Rehabilitation
More informationOptions for Treating Restless Legs Syndrome. A Review of the Research for Adults
Options for Treating Restless Legs Syndrome A Review of the Research for Adults Is This Information Right for Me? Yes, this information is for you if: Your doctor* has told you that you have restless legs
More informationDESCRIPTION.
Tapering off requip May 29, 2015. We conclude that for augmentation in RLS, gradual tapering of the there were four patients taking regular or extended length ropinirole with a mean. Of the 7 patients
More informationDiana Corzine, MD ABMS Sleep Chief MT VA Sleep Medicine Common Sleep Disorders
Diana Corzine, MD ABMS Sleep Chief MT VA Sleep Medicine 2018 Common Sleep Disorders Objectives: Understand Understand how Sleep Disorders affects health. Describe Describe some Common Sleep Disorders.
More informationAGING CHANGES IN SLEEP
OBJECTIVES: Understand the common age-related changes in sleep Discuss the evaluation of the older person with sleep complaints Identify sleep apnea, PLMS, RLS, and REM sleep disorders and their treatments
More informationSLEEP UPDATE 2008 SLEEP HYPNOGRAM. David Claman, MD UCSF Sleep Disorders Center
SLEEP UPDATE 2008 SLEEP HYPNOGRAM David Claman, MD UCSF Sleep Disorders Center Insomnia Case A 40 year old man c/o insomnia at sleep onset. He worries about sleep at night, and takes 2-3 hrs to fall asleep.
More informationComparative Effectiveness Review Number 86. Treatment for Restless Legs Syndrome
Comparative Effectiveness Review Number 86 Treatment for Restless Legs Syndrome Comparative Effectiveness Review Number 86 Treatment for Restless Legs Syndrome Prepared for: Agency for Healthcare Research
More informationPsychopharmacology of Sleep Disorders
Psychopharmacology of Sleep Disorders John W. Winkelman MD, PhD Chief, Sleep Disorders Clinical Research Program Departments of Psychiatry and Neurology Massachusetts General Hospital Professor of Psychiatry
More informationDiagnosis and treatment of sleep disorders
Diagnosis and treatment of sleep disorders Normal human sleep Sleep cycle occurs about every 90 minutes, approximately 4-6 cycles occur per major sleep episode NREM (70-80%) slow wave sleep heart rate,
More informationSleep and a Healthy Heart
Sleep and a Healthy Heart Dr. R. John Kimoff, MD, FRCP(C) Professor of Medicine, Respiratory Division Director, Sleep Laboratory, MCI-McGill University Health Centre Montréal, Québec, Canada Women s Healthy
More informationPeriodic Leg Movements in Narcolepsy
In: Nacrolepsy: Symptoms, Causes... ISBN: 978-1-60876-645-1 Editor: Guillermo Santos, et al. 2009 Nova Science Publishers, Inc. Chapter 7 Periodic Leg Movements in Narcolepsy Ahmed Bahammam * Sleep Disorders
More informationRuby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018
Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018 Objectives Describe pharmacology of commonly prescribed drugs for stimulants and hypnotics Brief review of common drugs that affect sleep
More informationPOLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 2012 PSYCHOPHARMACOLOGY SERIES. Guna Kanniah Waikato Hospital
POLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 212 PSYCHOPHARMACOLOGY SERIES Guna Kanniah Waikato Hospital POLYPHARMACY FIVE REASONS FOR POLYPHARMACY 1. To treat a concomitant disorder 2. To treat an
More informationR estless legs syndrome is a distressing sensorimotor
92 PAPER Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries C Trenkwalder, D Garcia-Borreguero,
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationDopamine agonists for the treatment of restless legs syndrome (Review)
Dopamine agonists for the treatment of restless legs syndrome (Review) Scholz H, Trenkwalder C, Kohnen R, Kriston L, Riemann D, Hornyak M This is a reprint of a Cochrane review, prepared and maintained
More informationRopinirole for the treatment of restless legs syndrome
EXPERT OPINION Ropinirole for the treatment of restless legs syndrome Clete A Kushida Stanford University Center of Excellence for Sleep Disorders, Stanford, CA, USA Abstract: Dopaminergic agents, anticonvulsants,
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?
More information(pramipexole hydrochloride monohydrate) The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole,
NAME OF THE MEDICINE Pramipexole hydrochloride monohydrate. SIFROL and SIFROL ER (pramipexole hydrochloride monohydrate) The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole,
More informationWalters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group..
Restless Legs Syndrome: Impact, Recognition, and Management Pierre Bou-Khalil Khalil, MD, FCCP, D ABSM What is RLS and what is its impact? Definition of RLS RLS is characterized by disagreeable leg sensations
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationRestless Legs Syndrome: Is This a Pain Issue?
Restless Legs Syndrome: Is This a Pain Issue? Kathy Lattavo, RN, MSN, ACNS- BC, RN-BC Objectives Describe the pathophysiology of RLS. Evaluate treatment for RLS. Compare & contrast RLS & pain. Definitions
More informationPRODUCT INFORMATION [SIMIPEX XR] (pramipexole hydrochloride monohydrate)
PRODUCT INFORMATION [SIMIPEX XR] (pramipexole hydrochloride monohydrate) NAME OF THE MEDICINE Pramipexole hydrochloride monohydrate. The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole,
More informationPramipexole hydrochloride. The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole,
SIFROL and SIFROL ER NAME OF THE MEDICINE Pramipexole hydrochloride. The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole, [C 10 H 17 N 3 S], CAS registry number
More informationSleep Disorders in Women s Health
Sleep Disorders in Women s Health Diana Corzine, MD, ABMS Sleep Chief, Sleep Medicine Service Montana VA Health Care System Helena, Montana Understand which sleep disorders commonly impact women s Understand
More informationIndex. baclofen 73 basal forebrain nuclei 174
Index acetazolamide 33 acetylcholine esterase inhibitor 174 actigraphy 14 activity meter 226 acute insomnia 4 α1 adrenergic activity 88 α 1 containing receptor 211 adenosine 108 advanced sleep phase syndrome
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Anxiolytic and Hypnotic Drugs Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 OTHER ANXIOLYTIC AGENTS/ A. Antidepressants Many antidepressants are effective in the treatment
More informationFacts about Sleep. Circadian rhythms are important in determining human sleep patterns/ sleep-waking cycle
Sleep Sleep is described as a state of unconsciousness or partial consciousness from which a person can be roused by stimulation Period of rest and recovery People spend about a third of their lives sleeping
More informationREVIEW ARTICLE. (RLS) is characterized by unpleasant sensations in. in the legs and a distressing, irresistible urge to move them.
REVIEW ARTICLE Pharmacologic Therapy for Primary Restless Legs Syndrome A Systematic Review and Meta-analysis Timothy J. Wilt, MD, MPH; Roderick MacDonald, MS; Jeannine Ouellette; Imran S. Khawaja, MD;
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationParkinson s Disease Psychosis: Hallucinations Delusions and Paranoia
Parkinson s Disease Psychosis: Hallucinations Delusions and Paranoia Christopher G. Goetz, MD Professor of Neurological Sciences Professor of Pharmacology Rush University Medical Center Parkinson s Foundation
More informationSleep & Wakefulness Disorders in Parkinson s Disease: The Challenge of Getting a Good Night s Sleep
Sleep & Wakefulness Disorders in Parkinson s Disease: The Challenge of Getting a Good Night s Sleep Helene A. Emsellem, MD March 25, 2017 The Center for Sleep & Wake Disorders PFNCA Symposium Sleep is
More informationTreatment of Restless Legs Syndrome Silvia Rios Romenets, MD Ronald B. Postuma, MD *
Current Treatment Options in Neurology (2013) 15:396 409 DOI 10.1007/s11940-013-0241-x MOVEMENT DISORDERS (O SUCHOWERSKY, SECTION EDITOR) Treatment of Restless Legs Syndrome Silvia Rios Romenets, MD Ronald
More informationRECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease
For the attention of Accredited Medical Writers Only RECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease Post hoc analyses of RECOVER study suggested
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More informationOverview of Sleep Medicine
Overview of Sleep Medicine Rodney Smith. New York Times 11-18-2007 James E. Mojica, MD, FAASM Pulmonary, Sleep, Critical Care Massachusetts General Hospital What is Sleep? Reversible state Perceptual disengagement
More informationNature, prevalence and clinical significance. Barcelona, Spain
Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1 Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated
More informationSleep - Definition. Slide 1 Sleep & Developmental Disabilities: Lessons for All Children. Slide 2 Importance of Sleep. Slide 3. Lawrence W.
1 Sleep & Developmental Disabilities: Lessons for All Children March 28, 2012 Lawrence W. Brown, MD Pediatric Neuropsychiatry Program Sleep Disorders Center The Children s Hospital of Philadelphia 2 Importance
More informationScottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More information